Crohn's disease
ICD-10 K50 · ICD-11 DD70

What to Do When Budesonide Has Not Achieved Remission in Mildly to Moderately Active Ileocecal Crohn's Disease

This protocol applies to adults with mildly to moderately active Crohn's disease affecting the terminal ileum and right colon (ileocecal region) who are at low risk for disease progression and have not achieved the expected symptomatic remission with initial therapy.

Clinical scenario: Mildly to moderately active Crohn's disease with ileocecal (terminal ileum and right colon) involvement, low risk for disease progression.

Previous therapy — goals not met

The first-line approach for this presentation is controlled ileal release budesonide (or, in patients with mild disease and low risk of progression, a diet-based strategy with careful monitoring). When this line of therapy fails to induce symptomatic remission — with clinical improvement expected within 2–4 weeks and maximal improvement by 12–16 weeks — escalation to the next step is indicated.

Next clinical step — overview

For patients who have not achieved the remission targets above, advanced biologic therapy — drawing on anti-TNF agents and other therapeutic classes — may be initiated for induction and maintenance of remission. The full structured protocol, including selection among available options based on individual patient profile, is detailed in the complete regimen.

At this stage, treatment goals include clinical and biomarker response within 12 weeks of initiation, followed by durable steroid-free clinical and endoscopic remission.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000003465

We recommend controlled ileal release budesonide at a dose of 9 mg daily for induction of symptomatic remission in patients with mildly to moderately active ileocecal CD (strong recommendation, moderate level of evidence).

For adult patients with mild CD and low risk of progression, diet-based strategies along with careful monitoring for inadequate symptom relief, worsening inflammation, or disease progression may be considered.

We suggest against requiring failure of conventional therapy before initiation of advanced therapy for the management of Crohn's disease (CD) (conditional recommendation, low level of evidence).

We recommend anti-tumor necrosis factor (TNF) agents (intravenous infliximab, subcutaneous adalimumab, subcutaneous certolizumab pegol) for induction and maintenance of remission for moderately to severely active CD (strong recommendation, moderate level of evidence).

Regimens are generally chosen according to the patient's risk profile and disease severity with a goal to achieve clinical and biomarker response within 12 weeks of treatment initiation followed by durable steroid-free control of disease activity including both clinical and endoscopic remission.

View source ↗